In this interview, Stephen J. Nicholls and Sotirios Tsimikas discuss AKCEA: Safety and Efficacy of AKCEA-APO(a)-to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial.